Top

Reviews in Endocrine and Metabolic Disorders

Published in:

10-06-2022 | Obesity

Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system

Authors: Omar Al-Massadi, Paolo Parini, Johan Fernø, Serge Luquet, Mar Quiñones

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 5/2022

Abstract

The growth hormone/insulin growth factor-1 axis is a key endocrine system that exerts profound effects on metabolism by its actions on different peripheral tissues but also in the brain. Growth hormone together with insulin growth factor-1 perform metabolic adjustments, including regulation of food intake, energy expenditure, and glycemia. The dysregulation of this hepatic axis leads to different metabolic disorders including obesity, type 2 diabetes or liver disease. In this review, we discuss how the growth hormone/insulin growth factor-1 axis regulates metabolism and its interactions with the central nervous system. Finally, we state our vision for possible therapeutic uses of compounds based in the components of this hepatic axis.

Collaboration NCDRF. Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019;569(7755):260–4. doi:https://doi.org/10.1038/s41586-019-1171-x.CrossRef

Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science. 1998;280(5368):1371–4. doi:https://doi.org/10.1126/science.280.5368.1371.CrossRefPubMed

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31. doi:https://doi.org/10.1056/NEJMra011775.CrossRefPubMed

Quinones M, Ferno J, Al-Massadi O. Ghrelin and liver disease. Reviews in endocrine & metabolic disorders. 2020;21(1):45–56. doi:https://doi.org/10.1007/s11154-019-09528-6.CrossRef

Al Massadi O, Nogueiras R, Dieguez C, Girault JA. Ghrelin and food reward. Neuropharmacology. 2019;148:131–8. doi:https://doi.org/10.1016/j.neuropharm.2019.01.001.CrossRefPubMed

Al-Massadi O, Dieguez C, Schneeberger M, Lopez M, Schwaninger M, Prevot V, et al. Multifaceted actions of melanin-concentrating hormone on mammalian energy homeostasis. Nat reviews Endocrinol. 2021;17(12):745–55. doi:https://doi.org/10.1038/s41574-021-00559-1.CrossRef

Jais A, Bruning JC. Arcuate nucleus-dependent regulation of metabolism - pathways to obesity and diabetes mellitus. Endocr Rev. 2021. doi:https://doi.org/10.1210/endrev/bnab025.CrossRefPubMedCentral

Al Massadi O, Lopez M, Tschop M, Dieguez C, Nogueiras R. Current Understanding of the Hypothalamic Ghrelin Pathways Inducing Appetite and Adiposity. Trends Neurosci. 2017;40(3):167–80. doi:https://doi.org/10.1016/j.tins.2016.12.003.CrossRefPubMed

Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science. 2005;310(5748):683–5. doi:https://doi.org/10.1126/science.1115524.CrossRefPubMed

10.

Quarta C, Claret M, Zeltser LM, Williams KW, Yeo GSH, Tschop MH, et al. POMC neuronal heterogeneity in energy balance and beyond: an integrated view. Nat Metab. 2021;3(3):299–308. doi:https://doi.org/10.1038/s42255-021-00345-3.CrossRefPubMedPubMedCentral

11.

Russek M. Participation of hepatic glucoreceptors in the control of intake of food. Nature. 1963;197:79–80. doi:https://doi.org/10.1038/197079b0.CrossRefPubMed

12.

Russek M. Current status of the hepatostatic theory of food intake control. Appetite. 1981;2(2):137–43. doi:https://doi.org/10.1016/s0195-6663(81)80007-4.CrossRefPubMed

13.

Tordoff MG, Friedman MI. Hepatic portal glucose infusions decrease food intake and increase food preference. Am J Physiol. 1986;251(1 Pt 2):R192-6. doi:https://doi.org/10.1152/ajpregu.1986.251.1.R192.CrossRefPubMed

14.

Bray GA, Campfield LA. Metabolic factors in the control of energy stores. Metab Clin Exp. 1975;24(1):99–117. doi:https://doi.org/10.1016/0026-0495(75)90011-6.CrossRefPubMed

15.

Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–71. doi:https://doi.org/10.1038/35007534.CrossRefPubMed

16.

Dieguez C, Casanueva FF. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol Metab. 1995;6(2):55–9. doi:https://doi.org/10.1016/1043-2760(94)00206-j.CrossRefPubMed

17.

Casanueva FF. Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am. 1992;21(3):483–517.CrossRef

18.

Ranke MB, Wit JM. Growth hormone - past, present and future. Nat reviews Endocrinol. 2018;14(5):285–300. doi:https://doi.org/10.1038/nrendo.2018.22.CrossRef

19.

Pombo M, Maccario M, Seoane LM, Tovar S, Micic D, Ghigo E, et al. Control and function of the GH-IGF-I axis in obesity. Eat Weight Disord. 2001;6(3 Suppl):22–7.PubMed

20.

Bidlingmaier M, Strasburger CJ. Growth hormone. Handb Exp Pharmacol. 2010(195):187–200. doi:https://doi.org/10.1007/978-3-540-79088-4_8.

21.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60. doi:https://doi.org/10.1038/45230.CrossRefPubMed

22.

Al-Massadi O, Gabellieri E, Trujillo ML, Senaris R, Pagotto U, Pasquali R, et al. Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent. J Neuroendocrinol. 2010;22(11):1127–36. doi:https://doi.org/10.1111/j.1365-2826.2010.02065.x.CrossRefPubMed

23.

Seoane LM, Tovar S, Baldelli R, Arvat E, Ghigo E, Casanueva FF, et al. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. Eur J Endocrinol. 2000;143(5):R7–9. doi:https://doi.org/10.1530/eje.0.143r007.CrossRefPubMed

24.

Peino R, Baldelli R, Rodriguez-Garcia J, Rodriguez-Segade S, Kojima M, Kangawa K, et al. Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol. 2000;143(6):R11-4. doi:https://doi.org/10.1530/eje.0.143r011.CrossRefPubMed

25.

Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, et al. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab. 2003;88(7):3450–3. doi:https://doi.org/10.1210/jc.2003-030211.CrossRefPubMed

26.

Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA. 2004;101(13):4679–84. doi:https://doi.org/10.1073/pnas.0305930101.CrossRefPubMedPubMedCentral

27.

Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. Front Endocrinol. 2018;9:35. doi:https://doi.org/10.3389/fendo.2018.00035.CrossRef

28.

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019;4:3. doi:https://doi.org/10.1038/s41392-019-0036-y.CrossRefPubMedPubMedCentral

29.

Hu B, Li H, Zhang XA, Balanced Act. The Effects of GH-GHR-IGF1 Axis on Mitochondrial Function. Front Cell Dev Biol. 2021;9:630248. doi:https://doi.org/10.3389/fcell.2021.630248.CrossRefPubMedPubMedCentral

30.

Chhabra Y, Lee CMM, Muller AF, Brooks AJ. GHR signalling: Receptor activation and degradation mechanisms. Mol Cell Endocrinol. 2021;520:111075. doi:https://doi.org/10.1016/j.mce.2020.111075.CrossRefPubMed

31.

Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology. 2006;147(6):2754–63. doi:https://doi.org/10.1210/en.2005-1549.CrossRefPubMed

32.

Steyn FJ, Xie TY, Huang L, Ngo ST, Veldhuis JD, Waters MJ, et al. Increased adiposity and insulin correlates with the progressive suppression of pulsatile GH secretion during weight gain. J Endocrinol. 2013;218(2):233–44. doi:https://doi.org/10.1530/JOE-13-0084.CrossRefPubMed

33.

List EO, Sackmann-Sala L, Berryman DE, Funk K, Kelder B, Gosney ES, et al. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr Rev. 2011;32(3):356–86. doi:https://doi.org/10.1210/er.2010-0009.CrossRefPubMed

34.

Berryman DE, List EO, Sackmann-Sala L, Lubbers E, Munn R, Kopchick JJ. Growth hormone and adipose tissue: beyond the adipocyte. Growth hormone & IGF research: official. J Growth Hormone Res Soc Int IGF Res Soc. 2011;21(3):113–23. doi:https://doi.org/10.1016/j.ghir.2011.03.002.CrossRef

35.

Berryman DE, List EO, Palmer AJ, Chung MY, Wright-Piekarski J, Lubbers E, et al. Two-year body composition analyses of long-lived GHR null mice. The journals of gerontology Series A, Biological sciences and medical sciences. 2010;65(1):31–40. doi:https://doi.org/10.1093/gerona/glp175.

36.

Piotrowska K, Borkowska SJ, Wiszniewska B, Laszczynska M, Sluczanowska-Glabowska S, Havens AM, et al. The effect of low and high plasma levels of insulin-like growth factor-1 (IGF-1) on the morphology of major organs: studies of Laron dwarf and bovine growth hormone transgenic (bGHTg) mice. Histol Histopathol. 2013;28(10):1325–36. doi:https://doi.org/10.14670/HH-28.1325.CrossRefPubMedPubMedCentral

37.

Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA. 1990;87(13):5061–5. doi:https://doi.org/10.1073/pnas.87.13.5061.CrossRefPubMedPubMedCentral

38.

Brooks NE, Hjortebjerg R, Henry BE, List EO, Kopchick JJ, Berryman DE. Fibroblast growth factor 21, fibroblast growth factor receptor 1, and beta-Klotho expression in bovine growth hormone transgenic and growth hormone receptor knockout mice. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society. 2016;30–31:22–30. doi:https://doi.org/10.1016/j.ghir.2016.08.003.CrossRef

39.

Sinha YN, Salocks CB, Vanderlaan WP. Prolactin and growth hormone secretion in chemically induced and genetically obese mice. Endocrinology. 1975;97(6):1386–93. doi:https://doi.org/10.1210/endo-97-6-1386.CrossRefPubMed

40.

Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD, et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab. 2001;86(11):5509–15. doi:https://doi.org/10.1210/jcem.86.11.8061.CrossRefPubMed

41.

Ozata M, Dieguez C, Casanueva FF. The inhibition of growth hormone secretion presented in obesity is not mediated by the high leptin levels: a study in human leptin deficiency patients. J Clin Endocrinol Metab. 2003;88(1):312–6. doi:https://doi.org/10.1210/jc.2002-020122.CrossRefPubMed

42.

Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth hormone and insulin-like growth factor I regulation of nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2022. doi:https://doi.org/10.1210/clinem/dgac088.CrossRefPubMed

43.

Liu Z, Cordoba-Chacon J, Kineman RD, Cronstein BN, Muzumdar R, Gong Z, et al. Growth Hormone Control of Hepatic Lipid Metabolism Diabetes. 2016;65(12):3598–609. doi:https://doi.org/10.2337/db16-0649.CrossRefPubMed

44.

Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, DiGirolamo DJ, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284(30):19937–44. doi:https://doi.org/10.1074/jbc.M109.014308.CrossRefPubMedPubMedCentral

45.

Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth hormone & IGF research: official. J Growth Hormone Res Soc Int IGF Res Soc. 2008;18(5):434–8. doi:https://doi.org/10.1016/j.ghir.2008.03.003.CrossRef

46.

Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut. 2003;52(6):914. doi:https://doi.org/10.1136/gut.52.6.914.CrossRefPubMedPubMedCentral

47.

Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol. 2012;167(1):67–74. doi:https://doi.org/10.1530/EJE-12-0252.CrossRefPubMed

48.

Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004;39(4):909–14. doi:https://doi.org/10.1002/hep.20140.CrossRefPubMed

49.

Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW, et al. Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly. J Clin Endocrinol Metab. 2017;102(11):4218–25. doi:https://doi.org/10.1210/jc.2017-01210.CrossRefPubMedPubMedCentral

50.

Winhofer Y, Wolf P, Krssak M, Wolfsberger S, Tura A, Pacini G, et al. No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2014;99(11):4299–306. doi:https://doi.org/10.1210/jc.2014-2242.CrossRefPubMed

51.

Minniti ME, Pedrelli M, Vedin LL, Delbes AS, Denis RGP, Oorni K, et al. Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans. Hepatology. 2020;72(2):656–70. doi:https://doi.org/10.1002/hep.31052.CrossRefPubMed

52.

Tateno C, Kataoka M, Utoh R, Tachibana A, Itamoto T, Asahara T, et al. Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver. Endocrinology. 2011;152(4):1479–91. doi:https://doi.org/10.1210/en.2010-0953.CrossRefPubMed

53.

Bartke A, Sun LY, Longo V. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiol Rev. 2013;93(2):571–98. doi:https://doi.org/10.1152/physrev.00006.2012.CrossRefPubMedPubMedCentral

54.

Vijayakumar A, Yakar S, Leroith D. The intricate role of growth hormone in metabolism. Front Endocrinol. 2011;2:32. doi:https://doi.org/10.3389/fendo.2011.00032.CrossRef

55.

Nielsen JH, Galsgaard ED, Moldrup A, Friedrichsen BN, Billestrup N, Hansen JA, et al. Regulation of beta-cell mass by hormones and growth factors. Diabetes. 2001;50(Suppl 1):25-9. doi:https://doi.org/10.2337/diabetes.50.2007.s25.CrossRef

56.

Donato J Jr, Wasinski F, Furigo IC, Metzger M, Frazao R. Central Regulation of Metabolism by Growth Hormone. Cells. 2021;10(1). doi:https://doi.org/10.3390/cells10010129.

57.

Furigo IC, Metzger M, Teixeira PD, Soares CR, Donato J Jr. Distribution of growth hormone-responsive cells in the mouse brain. Brain Struct function. 2017;222(1):341–63. doi:https://doi.org/10.1007/s00429-016-1221-1.CrossRef

58.

Sadagurski M, Landeryou T, Cady G, Kopchick JJ, List EO, Berryman DE, et al. Growth hormone modulates hypothalamic inflammation in long-lived pituitary dwarf mice. Aging Cell. 2015;14(6):1045–54. doi:https://doi.org/10.1111/acel.12382.CrossRefPubMedPubMedCentral

59.

Furigo IC, Teixeira PDS, de Souza GO, Couto GCL, Romero GG, Perello M, et al. Growth hormone regulates neuroendocrine responses to weight loss via AgRP neurons. Nat Commun. 2019;10(1):662. doi:https://doi.org/10.1038/s41467-019-08607-1.CrossRefPubMedPubMedCentral

60.

Bohlooly YM, Olsson B, Bruder CE, Linden D, Sjogren K, Bjursell M, et al. Growth hormone overexpression in the central nervous system results in hyperphagia-induced obesity associated with insulin resistance and dyslipidemia. Diabetes. 2005;54(1):51–62. doi:https://doi.org/10.2337/diabetes.54.1.51.CrossRefPubMed

61.

Quaresma PGF, Teixeira PDS, Furigo IC, Wasinski F, Couto GC, Frazao R, et al. Growth hormone/STAT5 signaling in proopiomelanocortin neurons regulates glucoprivic hyperphagia. Mol Cell Endocrinol. 2019;498:110574. doi:https://doi.org/10.1016/j.mce.2019.110574.CrossRefPubMedPubMedCentral

62.

Wasinski F, Furigo IC, Teixeira PDS, Ramos-Lobo AM, Peroni CN, Bartolini P, et al. Growth Hormone Receptor Deletion Reduces the Density of Axonal Projections from Hypothalamic Arcuate Nucleus Neurons. Neuroscience. 2020;434:136–47. doi:https://doi.org/10.1016/j.neuroscience.2020.03.037.CrossRefPubMed

63.

Zhong C, Song Y, Wang Y, Zhang T, Duan M, Li Y, et al. Increased food intake in growth hormone-transgenic common carp (Cyprinus carpio L.) may be mediated by upregulating Agouti-related protein (AgRP). Gen Comp Endocrinol. 2013;192:81–8. doi:https://doi.org/10.1016/j.ygcen.2013.03.024.CrossRefPubMed

64.

Freda PU, Reyes-Vidal C, Jin Z, Pugh M, Panigrahi SK, Bruce JN, et al. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy. J Clin Endocrinol Metab. 2019;104(11):5453–61. doi:https://doi.org/10.1210/jc.2019-01079.CrossRefPubMedPubMedCentral

65.

Haffer KN. Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice. J Anim Sci Biotechnol. 2012;3(1):21. doi:https://doi.org/10.1186/2049-1891-3-21.CrossRefPubMedPubMedCentral

66.

Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J Clin Endocrinol Metab. 2009;94(1):130–7. doi:https://doi.org/10.1210/jc.2008-1357.CrossRefPubMed

67.

Pan CS, Weiss JJ, Fourman LT, Buckless C, Branch KL, Lee H, et al. Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. Clin Endocrinol. 2021;94(2):183–92. doi:https://doi.org/10.1111/cen.14344.CrossRef

68.

Bredella MA, Gerweck AV, Lin E, Landa MG, Torriani M, Schoenfeld DA, et al. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. J Clin Endocrinol Metab. 2013;98(9):3864–72. doi:https://doi.org/10.1210/jc.2013-2063.CrossRefPubMedPubMedCentral

69.

Altabas V, Zjacic-Rotkvic V. Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy. Immunotargets Ther. 2015;4:123–30. doi:https://doi.org/10.2147/ITT.S60398.CrossRefPubMedPubMedCentral

70.

Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem. 2004;11(12):1595–615. doi:https://doi.org/10.2174/0929867043365026.CrossRefPubMed

71.

Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88(6):2586–92. doi:https://doi.org/10.1210/jc.2002-030003.CrossRefPubMed

72.

Al Massadi O, Lear PV, Muller TD, Lopez M, Dieguez C, Tschop MH, et al. Review of novel aspects of the regulation of ghrelin secretion. Curr Drug Metab. 2014;15(4):398–413. doi:https://doi.org/10.2174/1389200215666140505153723.CrossRefPubMed

73.

Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, et al. Vaccination against weight gain. Proc Natl Acad Sci USA. 2006;103(35):13226–31. doi:https://doi.org/10.1073/pnas.0605376103.CrossRefPubMedPubMedCentral

74.

Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol. 2007;33(2):176–89. doi:https://doi.org/10.1016/j.domaniend.2006.05.005.CrossRefPubMed

75.

Andrade S, Pinho F, Ribeiro AM, Carreira M, Casanueva FF, Roy P, et al. Immunization against active ghrelin using virus-like particles for obesity treatment. Curr Pharm Des. 2013;19(36):6551–8. doi:https://doi.org/10.2174/13816128113199990506.CrossRefPubMedPubMedCentral

76.

Takagi K, Legrand R, Asakawa A, Amitani H, Francois M, Tennoune N, et al. Anti-ghrelin immunoglobulins modulate ghrelin stability and its orexigenic effect in obese mice and humans. Nat Commun. 2013;4:2685. doi:https://doi.org/10.1038/ncomms3685.CrossRefPubMed

77.

AG; SCB. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss [webpage on the Internet] http://www.cytos.ch/news/180/15/Phase-I-IIa-clinical-trial-with-obese-individuals-shows-no-effect-of-CYT009-GhrQb-on-weight-loss.html. [Accessed January 3, 2015]. [updated November 7, 2006; cited January 3, 2015].

78.

Lamers CB. Clinical and pathophysiological aspects of somatostatin and the gastrointestinal tract. Acta Endocrinol Suppl (Copenh). 1987;286:19–25. doi:https://doi.org/10.1530/acta.0.115s019.CrossRef

79.

Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond). 2006;30(2):331–41. doi:https://doi.org/10.1038/sj.ijo.0803074.CrossRef

80.

Boehm BO, Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol. 2002;16(3):493–509. doi:https://doi.org/10.1053/bega.2002.0320.CrossRefPubMed

81.

Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr. 1999;135(2 Pt 1):162–8. doi:https://doi.org/10.1016/s0022-3476(99)70017-x.CrossRefPubMed

82.

Velasquez-Mieyer PA, Cowan PA, Arheart KL, Buffington CK, Spencer KA, Connelly BE, et al. Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. Int J Obes Relat metabolic disorders: J Int Association Study Obes. 2003;27(2):219–26. doi:https://doi.org/10.1038/sj.ijo.802227.CrossRef

83.

Velasquez-Mieyer PA, Umpierrez GE, Lustig RH, Cashion AK, Cowan PA, Christensen M, et al. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat metabolic disorders: J Int Association Study Obes. 2004;28(2):330–3. doi:https://doi.org/10.1038/sj.ijo.0802561.CrossRef

84.

Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997;336(9):633–40. doi:https://doi.org/10.1056/NEJM199702273360907.CrossRefPubMed

85.

Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J translational Med. 2016;14:3. doi:https://doi.org/10.1186/s12967-015-0762-z.CrossRef

86.

Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–54. doi:https://doi.org/10.1210/er.2001-0033.CrossRefPubMed

87.

Rotwein P. Diversification of the insulin-like growth factor 1 gene in mammals. PLoS ONE. 2017;12(12):e0189642. doi:https://doi.org/10.1371/journal.pone.0189642.CrossRefPubMedPubMedCentral

88.

Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050–93. doi:https://doi.org/10.1007/PL00000744.CrossRefPubMed

89.

Bano N, Hossain MM, Bhat AQ, Ayaz MO, Kumari M, Sandhu P, et al. Analyzing structural differences between insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society. 2020;55:101343. doi:https://doi.org/10.1016/j.ghir.2020.101343.CrossRef

90.

Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34. doi:https://doi.org/10.1210/edrv-16-1-3.CrossRefPubMed

91.

Franco C, Bengtsson BA, Johannsson G. The GH/IGF-1 Axis in Obesity: Physiological and Pathological Aspects. Metab Syndr Relat Disord. 2006;4(1):51–6. doi:https://doi.org/10.1089/met.2006.4.51.CrossRefPubMed

92.

Kreitschmann-Andermahr I, Suarez P, Jennings R, Evers N, Brabant G. GH/IGF-I regulation in obesity–mechanisms and practical consequences in children and adults. Hormone Res paediatrics. 2010;73(3):153–60. doi:https://doi.org/10.1159/000284355.CrossRef

93.

Paszynska E, Dmitrzak-Weglarz M, Slopien A, Tyszkiewicz-Nwafor M, Rajewski A. Salivary and serum insulin-like growth factor (IGF-1) assays in anorexic patients. world J Biol psychiatry: official J World Federation Soc Biol Psychiatry. 2016;17(8):615–21. doi:https://doi.org/10.3109/15622975.2015.1023356.CrossRef

94.

Rasmussen MH, Frystyk J, Andersen T, Breum L, Christiansen JS, Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metab Clin Exp. 1994;43(3):315–9. doi:https://doi.org/10.1016/0026-0495(94)90099-x.CrossRefPubMed

95.

Kunitomi M, Wada J, Takahashi K, Tsuchiyama Y, Mimura Y, Hida K, et al. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men. Int J Obes Relat metabolic disorders: J Int Association Study Obes. 2002;26(3):361–9. doi:https://doi.org/10.1038/sj.ijo.0801899.CrossRef

96.

Oh J, Kim JY, Park S, Youn JC, Son NH, Shin DJ, et al. The relationship between insulin-like growth factor-1 and metabolic syndrome, independent of adiponectin. Clinica chimica acta; international journal of clinical chemistry. 2012;413(3–4):506–10. doi:https://doi.org/10.1016/j.cca.2011.11.015.

97.

Mallea-Gil MS, Ballarino MC, Spiraquis A, Iriarte M, Kura M, Gimenez S, et al. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam. 2012;42(1):20–6.PubMed

98.

Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol. 2005;43(4):630–6. doi:https://doi.org/10.1016/j.jhep.2005.03.025.CrossRefPubMed

99.

Mauras N, O’Brien KO, Welch S, Rini A, Helgeson K, Vieira NE, et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab. 2000;85(4):1686–94. doi:https://doi.org/10.1210/jcem.85.4.6541.CrossRefPubMed

100.

Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol. 2006;6(6):620–5. doi:https://doi.org/10.1016/j.coph.2006.08.006.CrossRefPubMed

101.

Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 2001;15(15):1926–34. doi:https://doi.org/10.1101/gad.908001.CrossRefPubMedPubMedCentral

102.

Heron-Milhavet L, Haluzik M, Yakar S, Gavrilova O, Pack S, Jou WC, et al. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology. 2004;145(10):4667–76. doi:https://doi.org/10.1210/en.2003-1543.CrossRefPubMed

103.

Succurro E, Andreozzi F, Marini MA, Lauro R, Hribal ML, Perticone F, et al. Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2009;19(10):713–9. doi:https://doi.org/10.1016/j.numecd.2008.12.011.CrossRefPubMed

104.

Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002;359(9319):1740–5. doi:https://doi.org/10.1016/S0140-6736(02)08655-5.CrossRefPubMed

105.

Mannino GC, Greco A, De Lorenzo C, Andreozzi F, Marini MA, Perticone F, et al. A fasting insulin-raising allele at IGF1 locus is associated with circulating levels of IGF-1 and insulin sensitivity. PLoS ONE. 2013;8(12):e85483. doi:https://doi.org/10.1371/journal.pone.0085483.CrossRefPubMedPubMedCentral

106.

Rietveld I, Janssen JA, van Rossum EF, Houwing-Duistermaat JJ, Rivadeneira F, Hofman A, et al. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol. 2004;61(2):195–203. doi:https://doi.org/10.1111/j.1365-2265.2004.02078.x.CrossRef

107.

Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50(3):637–42. doi:https://doi.org/10.2337/diabetes.50.3.637.CrossRefPubMed

108.

Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD, et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest. 1995;25(6):403–11. doi:https://doi.org/10.1111/j.1365-2362.1995.tb01721.x.CrossRefPubMed

109.

Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Investig. 1994;93(3):1131–9. doi:https://doi.org/10.1172/JCI117065.CrossRefPubMedPubMedCentral

110.

Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996;45(1):91–100. doi:https://doi.org/10.2337/diab.45.1.91.CrossRefPubMed

111.

Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993;75(1):73–82.CrossRef

112.

Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat reviews Endocrinol. 2013;9(6):346–56. doi:https://doi.org/10.1038/nrendo.2013.64.CrossRef

113.

Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44(9):991–1005. doi:https://doi.org/10.1038/ng.2385.CrossRefPubMedPubMedCentral

114.

O’Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab. 2002;87(9):4356–60. doi:https://doi.org/10.1210/jc.2002-020343.CrossRefPubMed

115.

Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes. 2001;50(5):1110–8. doi:https://doi.org/10.2337/diabetes.50.5.1110.CrossRefPubMed

116.

Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Investig. 2004;113(1):96–105. doi:https://doi.org/10.1172/JCI17763.CrossRefPubMedPubMedCentral

117.

Mauras N, Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab. 1995;80(3):869–74. doi:https://doi.org/10.1210/jcem.80.3.7533772.CrossRefPubMed

118.

Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab. 1992;75(5):1186–91. doi:https://doi.org/10.1210/jcem.75.5.1430077.CrossRefPubMed

119.

Yuen KC, Dunger DB. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab. 2007;9(1):11–22. doi:https://doi.org/10.1111/j.1463-1326.2006.00591.x.CrossRefPubMed

120.

Bondy C, Werner H, Roberts CT Jr, LeRoith D. Cellular pattern of type-I insulin-like growth factor receptor gene expression during maturation of the rat brain: comparison with insulin-like growth factors I and II. Neuroscience. 1992;46(4):909–23. doi:https://doi.org/10.1016/0306-4522(92)90193-6.CrossRefPubMed

121.

Piriz J, Muller A, Trejo JL, Torres-Aleman I. IGF-I and the aging mammalian brain. Exp Gerontol. 2011;46(2–3):96–9. doi:https://doi.org/10.1016/j.exger.2010.08.022.CrossRefPubMed

122.

Deak F, Sonntag WE. Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1. The journals of gerontology Series A, Biological sciences and medical sciences. 2012;67(6):611–25. doi:https://doi.org/10.1093/gerona/gls118.

123.

Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, Vuguin P, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes. 2006;55(10):2788–96. doi:https://doi.org/10.2337/db06-0318.CrossRefPubMed

124.

Huffman DM, Farias Quipildor G, Mao K, Zhang X, Wan J, Apontes P, et al. Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. Aging Cell. 2016;15(1):181–6. doi:https://doi.org/10.1111/acel.12415.CrossRefPubMed

125.

Fujita S, Honda K, Yamaguchi M, Fukuzo S, Saneyasu T, Kamisoyama H. Role of Insulin-like Growth Factor-1 in the Central Regulation of Feeding Behavior in Chicks. J Poult Sci. 2019;56(4):270–6. doi:https://doi.org/10.2141/jpsa.0180127.CrossRefPubMedPubMedCentral

126.

Fujita S, Honda K, Hiramoto D, Gyu M, Okuda M, Nakayama S, et al. Central and peripheral administrations of insulin-like growth factor-1 suppress food intake in chicks. Physiol Behav. 2017;179:308–12. doi:https://doi.org/10.1016/j.physbeh.2017.07.001.CrossRefPubMed

127.

Lu H, Martinez-Nieves B, Lapanowski K, Dunbar J. Intracerebroventricular insulin-like growth factor-1 decreases feeding in diabetic rats. Endocrine. 2001;14(3):349–52. doi:https://doi.org/10.1385/ENDO:14:3:349.CrossRefPubMed

128.

Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev. 2009;30(5):494–535. doi:https://doi.org/10.1210/er.2009-0010.CrossRefPubMedPubMedCentral

129.

Backeljauw PF, Underwood LE. Therapy for 6.5–7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab. 2001;86(4):1504–10. doi:https://doi.org/10.1210/jcem.86.4.7381.CrossRefPubMed

130.

Azcona C, Preece MA, Rose SJ, Fraser N, Rappaport R, Ranke MB, et al. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clin Endocrinol. 1999;51(6):787–92. doi:https://doi.org/10.1046/j.1365-2265.1999.00887.x.CrossRef

131.

Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999;51(3):128–34. doi:https://doi.org/10.1159/000023345.CrossRefPubMed

132.

Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab. 2000;85(4):1518–24. doi:https://doi.org/10.1210/jcem.85.4.6559.CrossRefPubMed

133.

Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, et al. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab. 1995;80(4):1393–8. doi:https://doi.org/10.1210/jcem.80.4.7536209.CrossRefPubMed

134.

Haywood NJ, Slater TA, Matthews CJ, Wheatcroft SB. The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes. Mol metabolism. 2019;19:86–96. doi:https://doi.org/10.1016/j.molmet.2018.10.008.CrossRef

Title: Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system
Authors: Omar Al-Massadi
Paolo Parini
Johan Fernø
Serge Luquet
Mar Quiñones
Publication date: 10-06-2022
Publisher: Springer US
Keywords: Obesity
Obesity
Insulins
Insulins
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 5/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-022-09732-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

Vitamin D deficiency and cardiometabolic risk factors in adolescents: systematic review and meta-analysis

Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing’s syndrome: A systematic review and meta-analysis

Variable phenotypes of individual and family monogenic cases with hyperinsulinism and diabetes: a systematic review

Interactions between nuclear receptors glucocorticoid receptor α and peroxisome proliferator–activated receptor α form a negative feedback loop

Cognitive deficits in primary hyperparathyroidism – what we know and what we do not know: A narrative review

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials